EP2276502A4 - Compositions for the prevention and treatment of neuroinjury and methods of use thereof - Google Patents

Compositions for the prevention and treatment of neuroinjury and methods of use thereof

Info

Publication number
EP2276502A4
EP2276502A4 EP09820929A EP09820929A EP2276502A4 EP 2276502 A4 EP2276502 A4 EP 2276502A4 EP 09820929 A EP09820929 A EP 09820929A EP 09820929 A EP09820929 A EP 09820929A EP 2276502 A4 EP2276502 A4 EP 2276502A4
Authority
EP
European Patent Office
Prior art keywords
neuroinjury
prevention
compositions
treatment
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP09820929A
Other languages
German (de)
French (fr)
Other versions
EP2276502A1 (en
Inventor
Byron D Ford
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Morehouse School of Medicine Inc
Original Assignee
Morehouse School of Medicine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morehouse School of Medicine Inc filed Critical Morehouse School of Medicine Inc
Priority claimed from PCT/US2009/045019 external-priority patent/WO2010044917A1/en
Publication of EP2276502A1 publication Critical patent/EP2276502A1/en
Publication of EP2276502A4 publication Critical patent/EP2276502A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP09820929A 2008-05-23 2009-05-22 Compositions for the prevention and treatment of neuroinjury and methods of use thereof Withdrawn EP2276502A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7190108P 2008-05-23 2008-05-23
PCT/US2009/045019 WO2010044917A1 (en) 2009-05-22 2009-05-22 Compositions for the prevention and treatment of neuroinjury and methods of use thereof

Publications (2)

Publication Number Publication Date
EP2276502A1 EP2276502A1 (en) 2011-01-26
EP2276502A4 true EP2276502A4 (en) 2012-04-04

Family

ID=43384474

Family Applications (1)

Application Number Title Priority Date Filing Date
EP09820929A Withdrawn EP2276502A4 (en) 2008-05-23 2009-05-22 Compositions for the prevention and treatment of neuroinjury and methods of use thereof

Country Status (2)

Country Link
EP (1) EP2276502A4 (en)
AU (1) AU2009303786B2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999018976A1 (en) * 1997-10-14 1999-04-22 Cambridge Neuroscience, Inc. Therapeutic methods comprising use of a neuregulin
WO2006017184A2 (en) * 2004-07-09 2006-02-16 Wayne State University HYBRID PROTEINS WITH ErbB4 EXTRACELLULAR DOMAIN AND NEUREGULIN HEPARIN-BINDING DOMAIN FOR TARGETING
US20070155665A1 (en) * 2005-09-02 2007-07-05 Byron Ford Neuregulins for prevention and treatment of damage from acute assault on vascular and neuronal tissue and as regulators of neuronal stem cell migration

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999018976A1 (en) * 1997-10-14 1999-04-22 Cambridge Neuroscience, Inc. Therapeutic methods comprising use of a neuregulin
WO2006017184A2 (en) * 2004-07-09 2006-02-16 Wayne State University HYBRID PROTEINS WITH ErbB4 EXTRACELLULAR DOMAIN AND NEUREGULIN HEPARIN-BINDING DOMAIN FOR TARGETING
US20070155665A1 (en) * 2005-09-02 2007-07-05 Byron Ford Neuregulins for prevention and treatment of damage from acute assault on vascular and neuronal tissue and as regulators of neuronal stem cell migration

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of WO2010044917A1 *
XU Z ET AL: "Neuregulin-1 is neuroprotective and attenuates inflammatory responses induced by ischemic stroke", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 322, no. 2, 17 September 2004 (2004-09-17), pages 440 - 446, XP004527639, ISSN: 0006-291X, DOI: 10.1016/J.BBRC.2004.07.149 *

Also Published As

Publication number Publication date
AU2009303786A1 (en) 2010-07-29
EP2276502A1 (en) 2011-01-26
AU2009303786B2 (en) 2014-06-05

Similar Documents

Publication Publication Date Title
HRP20190059T1 (en) Compositions for the treatment of pain and/or inflammation
HK1250393A1 (en) Methods and compositions for the detection and treatment of preeclampsia
EP2361089A4 (en) Compositions and methods for the treatment of altered -synuclein function
HK1207594A1 (en) Compositions and methods for the prevention and treatment of autoimmune conditions
PL3208612T3 (en) Compositions and methods for the treatment of immune related diseases
HRP20160902T1 (en) Compositions and methods of use of phorbolesters
EP2212440A4 (en) Methods and compositions for the diagnosis and treatment of esphageal adenocarcinomas
HK1159498A1 (en) Methods and compositions for the treatment of cancer
EP2331123A4 (en) Compositions and methods for the treatment of hepatitis c
GB0718446D0 (en) Compositions and methods for the treatment of infection
HK1166305A1 (en) Compositions and methods for the treatment of inflammation
IL210997A0 (en) Compositions for the treatment of mrsa and uses thereof
EP2340027A4 (en) Methods and compositions for the treatment of cancer
IL196843A0 (en) Compositions and methods for the treatment of radiation proctosigmoitis
EP2249789A4 (en) Compositions and methods for the treatment of xerostomia
PL3216457T3 (en) Compounds and methods for the prevention or treatment of restenosis
EP2150270A4 (en) Methods and compositions for the treatment of cancer
EP2285398A4 (en) Methods and compositions for the treatment of obesity
EP2142566A4 (en) Methods and compositions for the treatment of proliferative diseases
EP2480099A4 (en) Compositions and methods for the prevention and treatment of metabolic diseases
EP2370087A4 (en) Methods and compositions for the treatment of fluid retention disorders
GB0808326D0 (en) Compositions and methods for the treatment of fybromyalgia
GB0808730D0 (en) Compositions and methods for the prevention and treatment of schistosomiasis
EP2276502A4 (en) Compositions for the prevention and treatment of neuroinjury and methods of use thereof
EP2274042A4 (en) Treatment and/or prevention of multiple sclerosis

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20100430

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA RS

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20120301

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 25/28 20060101ALI20120224BHEP

Ipc: A61K 38/18 20060101AFI20120224BHEP

17Q First examination report despatched

Effective date: 20130228

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20140422

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20140903